Libo Pharma starts drug project with Japan universityStaff writerTaipei-based Libo Pharma on Tuesday led a delegation to Japan’s Fukushima Prefecture to launch a collaborative project with Fukushima Medical University in emergency radiation medicine. The collaboration would be based on LIB-101, Libo Pharma’s core investigational drug, which is under development, with the researchers to conduct an investigator-initiated trial (IIT) to study its application in medical management following major radiation accidents. Members of a Libo Pharma delegation pose for a photograph in Fukushima, Japan, yesterday after attending a ceremony commemorating the 15th anniversary of the Tohoku earthquake disasters. Photo courtesy of Libo Pharma CoFollowing the disaster, Japan established a comprehensive nuclear disaster medical and radiation accident response system, and has become a hub for global nuclear disaster medical research and policy development. Lin Shih-chia (林世嘉), executive director of the Foundation of Medical Professionals Alliance in Taiwan, said that Fukushima Medical University is a leading research institution in nuclear disaster medicine and radiation science.

Source: Taipei Times March 11, 2026 17:43 UTC